The AMBAR (Alzheimer Management By Albumin Replacement) study (EudraCT# 2011‐001598‐25; ClinicalTrials.gov ID: NCT01561053) used a therapeutic approach for Alzheimer's disease (AD) based on plasma exchange (PE) with albumin replacement (PE‐Alb).1 This evidence concerns the gene ALB and early-onset autosomal dominant Alzheimer disease.